Abstract
Portal hypertension is caused primarily by obstruction of the hepatic vasculature. In cirrhosis, the obstruction involves mostly obliteration of small hepatic venules and portal venules. There is a reflex increase in arterial flow that contributes to the portal hypertension. It is becoming known that cirrhosis is to some degree reversible. This chapter will review the pathogenesis of cirrhosis and its reversal from the perspective of hepatic vascular disease.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Wanless IR, Nakashima E, Sherman M. Regression of human cirrhosis: morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med. 2000;124:1599–607.
Wanless IR. Cirrhosis. In: Johnson LR, ed. Encyclopedia of Gastroenterology. New York: Academic Press; 2003:356–62.
Wanless IR, Crawford JM. Cirrhosis. In: Odze RD, Goldblum JR, Crawford JM, eds. Surgical Pathology of the Alimentary Tract, Pancreas, Biliary Tree, and Liver. Philadelphia: Saunders; 2004:863–84.
Wanless IR, Liu JJ, Butany J. Role of thrombosis in the pathogenesis of congestive hepatic fibrosis (cardiac cirrhosis). Hepatology. 1995;21:1232–7.
Tanaka M, Wanless IR. Pathology of the liver in Budd-Chiari syndrome: portal vein thrombosis and the histogenesis of veno-centric cirrhosis, veno-portal cirrhosis, and large regenerative nodules. Hepatology. 1998:27:488–96.
Moreno-Merlo F, Wanless IR, Shimamatsu K, Sherman M, Greig P, Chiasson D. The role of granulomatous phlebitis and thrombosis in the pathogenesis of cirrhosis and portal hypertension in sarcoidosis. Hepatology. 1997;26:554–60.
Wanless IR, Shiota K. The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin Liver Dis. 2004;24:99–106.
Fauerholdt L, Schlichting P, Christensen E, Poulsen H, Tygstrup N, Juhl E. Conversion of micronodular cirrhosis into macronodular cirrhosis. Hepatology. 1983;3:928–31.
Lewis DR, Burbige EJ, French SW. Reversal of cirrhosis in hemochromatosis following long-term phlebotomy. Gastroenterology. 1983;84: 1382.
Grand RJ, Vawter GF. Juvenile Wilson disease: histologic and functional studies during penicillamine therapy. J Pediatr. 1975;87:1161–70.
Dufour JF, DeLellis R, Kaplan MM. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med. 1997;127:981–5.
Bunton GL, Cameron R. Regeneration of liver after biliary cirrhosis. Ann NY Acad Sci. 1963;111:412–21.
Villeneuve JP, Condreay LD, Willems B et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology. 2000;31:207–10.
Poynard T, McHutchison J, Davis GL et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology. 2000;32:1131–7.
Nakashima E, Kage M, Wanless IR. Idiopathic portal hypertension: Histologic evidence that some cases may be regressed cirrhosis with portal vein thrombosis. Hepatology. 1999;30:218A.
Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology. 1995;21:1238–47.
Ward N, Haninec AL, Van Slyke P et al. Angiopoietin-1 causes reversible degradation of the portal microcirculation in mice: implications for treatment of liver disease. Am J Pathol. 2004; in press.
Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825–32.
Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–9.
Scheuer P. Primary biliary cirrhosis. Proc R Soc Med. 1967;60:1257–60.
Ludwig J. Etiology of biliary cirrhosis: diagnostic features and a new classification. Zentralbl Allg Pathol. 1988;134: 132–41.
Wanless IR, Sweeney G, Dhillon AP et al. Lack of progressive hepatic fibrosis during longterm therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood. 2002:100:1566–9.
Wanless IR, Takayama A. Evaluation of regressed cirrhosis on biopsy using the vein/artery ratio. Hepatology. 2004; in press.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer Science+Business Media Dordrecht
About this paper
Cite this paper
Wanless, I.R. (2004). Structural changes in the liver leading to cirrhosis and portal hypertension. In: Groszmann, R.J., Bosch, J. (eds) Portal Hypertension in the 21st Century. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-1042-9_6
Download citation
DOI: https://doi.org/10.1007/978-94-007-1042-9_6
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-3774-7
Online ISBN: 978-94-007-1042-9
eBook Packages: Springer Book Archive